Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.3
3.2
Journals
Life
Special Issues
Advancements in Heart Failure Research
share announcement

Advancements in Heart Failure Research

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (31 January 2025) | Viewed by 18321

Special Issue Editors

Prof. Dr. Tzu-Hurng Cheng

E-Mail Website
Guest Editor
Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91, Xueshi Road, North District, Taichung City 404328, Taiwan
Interests: biochemistry; signal transduction; molecular cardiology; natural products; cardiovascular pharmacology
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Ju-Chi Liu

E-Mail Website
Guest Editor
Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, Taipei City, Taiwan
Interests: heart failure; cardiac remodeling; biomarkers; precision medicine; patient-centered care; therapeutic innovations; molecular cardiology; signal transduction
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Heart failure persists as a significant global health challenge despite strides in treatment and this Special Issue aims to comprehensively explore recent advancements in heart failure research, from its roots to innovative interventions. understanding the intricate mechanisms driving heart failure is essential to effective management and articles submitted to this Special Issue will delve into pathophysiological processes such as myocardial remodeling, neurohormonal activation, and genetic predispositions. Moreover, this Special Issue seeks to navigate emerging diagnostic modalities such as novel biomarkers, advanced imaging techniques, and artificial intelligence applications, which may prove crucial for timely and accurate diagnosis.

Highlighting the latest therapeutic strategies, from pharmacological interventions to device-based therapies and surgical procedures, this Special Issue underscores precision-medicine approaches, innovative drug therapies, and the role of cardiac devices such as ventricular assist devices and cardiac transplantation. Managing heart failure alongside comorbidities poses unique challenges, addressed in discussions on strategies to tackle common issues such as hypertension, diabetes, and chronic kidney disease. Fostering patient-centered care remains paramount, with a focus on holistic approaches, remote monitoring technologies, and strategies promoting adherence to self-care and treatment.

Lastly, this Special Issue anticipates future trends, examining promising avenues like regenerative medicine and the integration of digital health technologies in personalized care. By bringing together cutting-edge research and insights from leading experts in the field, this Special Issue aims to advance our understanding of heart failure and pave the way toward improved management strategies and patient outcomes.

We invite researchers and clinicians to contribute original research articles, reviews, and perspectives to this Special Issue, with the goal of fostering collaboration and driving innovation in the field of heart failure research.

Prof. Dr. Tzu-Hurng Cheng
Prof. Dr. Ju-Chi Liu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiac remodeling
  • biomarkers
  • precision medicine
  • patient-centered care
  • therapeutic innovations

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (11 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 649 KiB  
Article
A Prospective Clinical Study of Ferric Citrate Hydrate for Chronic Heart Failure with Iron Deficiency Anemia
by Akira Sezai, Hisakuni Sekino, Makoto Taoka, Kazuaki Obata, Sakie Kanno and Masashi Tanaka
Life 2025, 15(4), 598; https://doi.org/10.3390/life15040598 - 3 Apr 2025
Viewed by 483
Abstract
Background: The efficacy of intravenous iron preparations for chronic heart failure with iron deficiency has been reported, but the efficacy of oral iron preparations has not been demonstrated. In this study, we conducted a prospective clinical study using ferric citrate hydrate tablets in [...] Read more.
Background: The efficacy of intravenous iron preparations for chronic heart failure with iron deficiency has been reported, but the efficacy of oral iron preparations has not been demonstrated. In this study, we conducted a prospective clinical study using ferric citrate hydrate tablets in patients with chronic heart failure complicated by iron deficiency anemia. Methods and Results: A prospective study was conducted using ferric citrate hydrate in patients with chronic heart failure complicated by iron deficiency anemia. The registered patients were divided into two groups: those administered ferric citrate hydrate and those switched from iron sulfate sustained-release to ferric citrate hydrate. The primary endpoint was hemoglobin level. The secondary endpoints included hematocrit, serum iron, saturation, ferritin, and cardiac-, renal-, and hepatic-related biomarkers. A total of 141 patients were enrolled in this study, including 95 patients who were newly administered ferric citrate hydrate and 46 patients who were switched from iron sulfate sustained-release to ferric citrate hydrate. Conclusions: Ferric citrate hydrate significantly increased hemoglobin, serum iron, transferrin saturation (TSAT), and ferritin levels, and decreased atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels. Ferric citrate hydrate could be continued without side effects such as gastrointestinal symptoms. Improvement in iron metabolism and anemia due to iron supplementation with ferric citrate hydrate led to improvement in heart failure biomarkers. Full article
(This article belongs to the Special Issue Advancements in Heart Failure Research)
►▼ Show Figures

Figure 1

17 pages, 3536 KiB  
Article
Liraglutide Treatment Restores Cardiac Function After Isoprenaline-Induced Myocardial Injury and Prevents Heart Failure in Rats
by Zorislava Bajic, Tanja Sobot, Aleksandra Smitran, Snezana Uletilovic, Nebojša Mandić-Kovačević, Tanja Cvjetkovic, Ugljesa Malicevic, Bojan Stanetic, Đorđe Đukanović, Milka Maticic, Sanja Jovicic, Dragan M. Djuric, Milos P. Stojiljkovic and Ranko Skrbic
Life 2025, 15(3), 443; https://doi.org/10.3390/life15030443 - 12 Mar 2025
Viewed by 645
Abstract
Background: Myocardial injury (MI) is characterized by an increased level of at least one cardiac troponin. Experimental MI can be induced by isoprenaline, a β-adrenergic agonist, and it can lead to heart failure (HF). Liraglutide is glucagon-like 1 peptide receptor agonist used in [...] Read more.
Background: Myocardial injury (MI) is characterized by an increased level of at least one cardiac troponin. Experimental MI can be induced by isoprenaline, a β-adrenergic agonist, and it can lead to heart failure (HF). Liraglutide is glucagon-like 1 peptide receptor agonist used in diabetes management, but it has anti-inflammatory and antioxidative effects, which can be beneficial in treatment of HF. The aim of this study was to investigate the effects of liraglutide on isoprenaline-induced MI and prevention of HF. Methods: Male Wistar albino rats were divided into four groups: Con—received saline the first 2 days + saline the next 7 days; Iso—isoprenaline the first 2 days + saline the next 7 days; Lir—saline the first 2 days + liraglutide the next 7 days; Iso + Lir—isoprenaline the first 2 days + liraglutide the next 7 days. On day 10, blood samples were taken for biochemical analysis and oxidative stress marker evaluation, and hearts were isolated for pathohistological analysis. Cardiac function was assessed by electrocardiography (ECG) and echocardiography (ECHO). Results: Liraglutide treatment significantly attenuated oxidative stress, repaired ECG and ECHO parameters, and mitigated myocardial morphological changes induced by isoprenaline. Conclusions: Liraglutide restores cardiac function in isoprenaline-induced HF. Full article
(This article belongs to the Special Issue Advancements in Heart Failure Research)
►▼ Show Figures

Figure 1

19 pages, 1899 KiB  
Article
High and Low Adherence to Mediterranean and DASH Diet Patterns and the Risk of Heart Failure: A Meta-Analysis of Observational Studies
by Mehmet Emin Arayici, Mustafa Eray Kilic and Mehmet Birhan Yilmaz
Life 2025, 15(1), 63; https://doi.org/10.3390/life15010063 - 7 Jan 2025
Viewed by 1638
Abstract
Background. The relationship between heart failure (HF) and Mediterranean and DASH diets is not well delineated. This meta-analysis aimed to assess the effectiveness of high adherence to Mediterranean and DASH diets compared to low adherence in reducing the risk of incident HF (primary [...] Read more.
Background. The relationship between heart failure (HF) and Mediterranean and DASH diets is not well delineated. This meta-analysis aimed to assess the effectiveness of high adherence to Mediterranean and DASH diets compared to low adherence in reducing the risk of incident HF (primary prevention of HF) and reducing all-cause mortality in patients with HF (secondary prevention of HF). Methods. The reporting stages of this meta-analysis closely adhered to the PRISMA guidelines. A comprehensive literature search was undertaken for published papers in PubMed, Embase, EBSCO, ICTRP, and the NIH clinical trials databases. Results. A total of 16 reports from 14 studies were included in this paper. A significant inverse association was identified between high adherence to the Mediterranean diet model (compared to low adherence) and the risk of incident HF (OR = 0.77, 95% CI: 0.63–0.93, p = 0.007) among patients without previous diagnosis of HF. Similarly, there was a significant and inverse relationship between high adherence to the DASH diet (compared to low adherence) and the risk of incident HF (OR = 0.83, 95% CI: 0.70–0.98, p = 0.03) among patients without previous diagnosis of HF. High adherence to the Mediterranean diet model (compared to low adherence) was associated with lower all-cause mortality (OR = 0.88, 95% CI: 0.78–0.99, p = 0.03) among patients with HF. Conclusions. This paper demonstrated that high adherence to Mediterranean and DASH diets significantly reduced the risk of incident HF among individuals without a previous diagnosis of HF, whereas only high adherence to the Mediterranean diet was associated with lower all-cause mortality among patients with HF. Full article
(This article belongs to the Special Issue Advancements in Heart Failure Research)
►▼ Show Figures

Graphical abstract

20 pages, 6210 KiB  
Article
Clinicopathological Studies on the Impact of Grape Seed Extract and L-Carnitine as Cardioprotective Agents Against Doxorubicin-Induced Toxicity in Rats
by Tahany Saleh Aldayel, Omnia E. Kilany, Heba Nageh Gad El-Hak, Heba M. A. Abdelrazek, Osama Abdallah and Donia E. Omar
Life 2024, 14(12), 1656; https://doi.org/10.3390/life14121656 - 13 Dec 2024
Viewed by 1173
Abstract
Doxorubicin (DOX) cancer therapy induces serious cardiotoxicity as a side effect. This study aimed to investigate the cardioprotective effects of grape seed extract (GSE) and L-Carnitine (L-CA) against DOX-induced cardiac toxicity in male rats. Six groups of male albino rats were used: G1 [...] Read more.
Doxorubicin (DOX) cancer therapy induces serious cardiotoxicity as a side effect. This study aimed to investigate the cardioprotective effects of grape seed extract (GSE) and L-Carnitine (L-CA) against DOX-induced cardiac toxicity in male rats. Six groups of male albino rats were used: G1 (control); G2 (GSE), given grape seed extract (100 mg/kg b.wt.) orally for 35 days; G3 (L-CA) (150 mg/kg b.wt.); Group 4 (DOX-induced cardiotoxicity), given DOX (10 mg/kg b.wt., i.p.) on the 28th day of the experiment; G5 (GSE + DOX), given GSE and DOX as previously mentioned; and G6 (L-CA + DOX), given L-CA and DOX as previously mentioned. Electrocardiographic evaluation, lipid profile, lipid peroxidation and antioxidants, serum cardiac markers, and inflammatory markers were estimated. Histopathological evaluation of cardiac tissue was also examined. Key findings showed that DOX induced ECG abnormalities lipid peroxidation, reduced antioxidants, and elevated cardiac and inflammatory markers. GSE and L-CA significantly ameliorated ECG abnormalities, reduced lipid peroxidation, improved antioxidant enzymes and serum cardiac markers, and reduced inflammation. These findings suggest that GSE and L-CA exhibit substantial cardioprotective effects in DOX-induced cardiotoxicity via their antioxidant and anti-inflammatory potentials. Full article
(This article belongs to the Special Issue Advancements in Heart Failure Research)
►▼ Show Figures

Figure 1

19 pages, 3137 KiB  
Article
The Relationship Between the Kansas City Cardiomyopathy Questionnaire and Electrocardiographic Parameters in Predicting Outcomes After Cardiac Resynchronization Therapy
by Andrei-Mihnea Rosu, Luminita-Florentina Tomescu, Theodor-Georgian Badea, Emanuel-Stefan Radu, Andreea-Liana Rosu, Lavinia-Nicoleta Brezeanu, Maria-Daniela Tanasescu, Sebastian Isac, Teodora Isac, Oana-Andreea Popa and Crina-Julieta Sinescu
Life 2024, 14(12), 1564; https://doi.org/10.3390/life14121564 - 28 Nov 2024
Viewed by 791
Abstract
Background: Cardiac resynchronization therapy (CRT) is an essential treatment for patients with symptomatic heart failure and ventricular conduction abnormalities. Low-ejection-fraction (EF) cardiomyopathy often involves a wide QRS complex displaying a left bundle branch block (LBBB) morphology and markedly delayed activation of the LV [...] Read more.
Background: Cardiac resynchronization therapy (CRT) is an essential treatment for patients with symptomatic heart failure and ventricular conduction abnormalities. Low-ejection-fraction (EF) cardiomyopathy often involves a wide QRS complex displaying a left bundle branch block (LBBB) morphology and markedly delayed activation of the LV lateral wall. Following CRT, patients with heart failure and LBBB have better outcomes and quality-of-life improvements. Various electrocardiographic and clinical parameters are thought to be able to predict this improvement. The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a reliable tool for measuring these patients’ quality of life. Methods: This is an observational prospective study featuring over 69 individuals diagnosed with cardiac failure and dilatative cardiomyopathy with low-EF and major LBBB. This study analyzed the correlations between patient outcomes and demographic, clinical, and electrocardiographic parameters. Results: Following the analysis, we observed correlations between the QRS area, intraprocedural systolic blood pressure, Q-LV interval, the R-wave amplitude in the right precordial leads and the CRT outcomes indicated by the KCCQ score. Conclusions: The parameters found and their correlation with the KCCQ score show how CRT therapy impacts patients’ quality of life, symptom burden, and functional status. Full article
(This article belongs to the Special Issue Advancements in Heart Failure Research)
►▼ Show Figures

Figure 1

13 pages, 267 KiB  
Article
Lipid Accumulation Product and Cardiometabolic Index as Effective Tools for the Identification of Athletes at Risk for Metabolic Syndrome
by Giuseppe Di Gioia, Armando Ferrera, Mihail Celeski, Raffaella Mistrulli, Erika Lemme, Federica Mango, Maria Rosaria Squeo and Antonio Pelliccia
Life 2024, 14(11), 1452; https://doi.org/10.3390/life14111452 - 8 Nov 2024
Cited by 1 | Viewed by 966
Abstract
Introduction: Metabolic syndrome (MS) is a growing global public health concern that is associated with increased risk for cardiovascular events, even in athletes. The lipid accumulation product (LAP) index and cardiometabolic index (CMI) have been shown to be efficient markers of MS in [...] Read more.
Introduction: Metabolic syndrome (MS) is a growing global public health concern that is associated with increased risk for cardiovascular events, even in athletes. The lipid accumulation product (LAP) index and cardiometabolic index (CMI) have been shown to be efficient markers of MS in the general population; its applicability in athletes has not been discussed yet. We aimed to assess the role of LAP and CMI in predicting MS in athletes. Methods: We retrospectively enrolled 793 Olympic athletes practicing different sporting disciplines (power, skill, endurance, and mixed), classified arbitrarily into no risk (NR), low risk (LR), high risk (HR), or MS if they had 0, 1, 2, or 3 criteria for MS, respectively. Evaluations included a calculation of the LAP index, CMI, anthropometric measurements, and clinical and laboratorial variables. Results: Among our population, only 0.8% reached the criteria for MS, 9.1% were at HR for MS, 37.8% were defined as LR, and 52.3% had NR. Significant differences in anthropometric parameters and the principal components of MS criteria (blood pressure, lipidic profile, glycemia) were reported predominantly in HR athletes and those with MS (p < 0.0001). LAP and CMI presented linearly increasing values from individuals with NR to those with MS (p < 0.0001). In addition, HR and MS athletes were classified as “likely MS” (9.8%) and LR and NR athletes as “unlikely MS” (90.2%). After adjusting for potential confounders, LAP ≥ 34.66 and CMI ≥ 0.776 emerged as independent predictors for MS in the overall cohort (Hazar Ratio (HR) 7.22 [3.75–13.89], p < 0.0001, and HR 5.37 [2.96–9.73], p < 0.0001, respectively). The ROC curve revealed that these cut-offs in the general population predict MS with an area under the curve (AUC) of 0.80 and 0.79, respectively, for LAP and CMI. However, gender-related cut-offs seem to be more precise in predicting MS (LAP ≥ 38.79 for male, LAP ≥ 14.16 for female, and CMI ≥ 0.881 for male and ≥0.965 for female). Conclusion: The ROC curve analyses of LAP and CMI showed good diagnostic accuracy in predicting MS among athletes, despite the low prevalence of MS in our sample. Thus, these indexes may be used to promote screening for primary prevention and early detection of athletes at risk for MS to establish an early prevention strategy. Larger prospective studies are necessary to validate their benefit in the general population. Full article
(This article belongs to the Special Issue Advancements in Heart Failure Research)
10 pages, 1324 KiB  
Article
Lymphocyte to White Blood Cell Count Ratio an Independent Risk Factor for Heart Failure
by Lior Charach, Avishay Spitzer, Lior Zusmanovitch and Gideon Charach
Life 2024, 14(10), 1266; https://doi.org/10.3390/life14101266 - 5 Oct 2024
Cited by 1 | Viewed by 1580
Abstract
Objective: Heart failure affects 1–2% of the population in developed countries. Hemogram biomarkers are cheap, rapid, readily accessible and are known to have prognostic benefit in cardiovascular, infectious and oncologic diseases. Methods: The aim of the current study is to evaluate lymphocyte-to-white-blood-cell ratio [...] Read more.
Objective: Heart failure affects 1–2% of the population in developed countries. Hemogram biomarkers are cheap, rapid, readily accessible and are known to have prognostic benefit in cardiovascular, infectious and oncologic diseases. Methods: The aim of the current study is to evaluate lymphocyte-to-white-blood-cell ratio (LWR) as a prognostic predictor in patients with heart failure. Patients with heart failure were recruited between January 2000 and July 2001. Exclusion criteria included metastatic malignancy, exposure to chemotherapy, radiotherapy or medications known to affect complete blood count. Results: 338 patients were enrolled, 33 were excluded. Mean age was 70.1 ± 10.8, 225 patients were male (73%) and 80 were female (27%). All patients were divided into three groups according to LWR. Group 1 < 0.2, group 2—0.2 < LWR < 0.35 and group 3 > 0.35. Patients with LWR ratio < 0.2 had the poorest survival while patients in the highest LWR (ratio > 0.35) had the best long-term survival. Conclusions: Patients with congestive heart failure and LWR < 0.2 showed significant increased mortality. LWR was shown as independent prognostic predictor for HF patients compared to other main outcome parameters, including CRP, NYHA, EF and LDL. Full article
(This article belongs to the Special Issue Advancements in Heart Failure Research)
►▼ Show Figures

Figure 1

Review

Jump to: Research

23 pages, 834 KiB  
Review
Perioperative Considerations of Novel Antidiabetic Agents in Heart Failure Patients Undergoing Cardiac Surgery
by Ashley Wang, Savannah Bitzas, Dilsa Perez, Jonathon Schwartz, Saleem Zaidi, Jonathan Oster and Sergio D. Bergese
Life 2025, 15(3), 427; https://doi.org/10.3390/life15030427 - 8 Mar 2025
Viewed by 892
Abstract
Diabetes mellitus (DM) is a major risk factor for cardiovascular disease, including heart failure (HF). A high proportion of DM patients eventually require cardiac surgery. While the traditional approach to DM therapy focuses on tight glucose control with insulin and oral hypoglycemic agents, [...] Read more.
Diabetes mellitus (DM) is a major risk factor for cardiovascular disease, including heart failure (HF). A high proportion of DM patients eventually require cardiac surgery. While the traditional approach to DM therapy focuses on tight glucose control with insulin and oral hypoglycemic agents, novel antidiabetic drugs have emerged over the past two decades that offer not only improved glycemic control but also cardiovascular and renal protection, such as benefits in HF management. The aim of this review is to examine and evaluate the perioperative risk and benefits of novel antidiabetic agents in HF treatment for both DM and non-DM patients undergoing cardiac surgery. We specifically studied glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium–glucose cotransporter 2 inhibitors (SGLT2is). Although studies on novel antidiabetic therapy in cardiac surgeries were limited, the results showed all three agents to be safe for use in the perioperative period, with SLGT2i demonstrating the most benefits in HF management for those with or without DM and kidney impairment undergoing cardiac surgery. Future research on larger study populations and using a more rigorous study design is necessary in bridging current knowledge to improve patient outcomes. Full article
(This article belongs to the Special Issue Advancements in Heart Failure Research)
►▼ Show Figures

Figure 1

19 pages, 2953 KiB  
Review
Left Atrial Strain in Patients with Chronic Heart Failure with Preserved Ejection Fraction: A Narrative Review
by Dana Emilia Man, Alexandru Catalin Motofelea, Valentina Buda, Dana Emilia Velimirovici, Olivia Bodea, Daniel Marius Duda-Seiman, Constantin Tudor Luca and Simona-Ruxanda Dragan
Life 2025, 15(2), 313; https://doi.org/10.3390/life15020313 - 17 Feb 2025
Viewed by 1167
Abstract
Background: Heart failure with preserved ejection fraction (HFpEF) represents a significant portion of heart failure cases, but diagnosis is challenging due to its diverse presentation and the limitations of traditional echocardiographic parameters. Left atrial (LA) strain provides valuable insights into LA function and [...] Read more.
Background: Heart failure with preserved ejection fraction (HFpEF) represents a significant portion of heart failure cases, but diagnosis is challenging due to its diverse presentation and the limitations of traditional echocardiographic parameters. Left atrial (LA) strain provides valuable insights into LA function and is increasingly used to evaluate cardiac function, including left ventricular (LV) diastolic function. LA strain, particularly reservoir strain, is considered a reliable indicator of LV diastolic function and can be used to grade diastolic function and estimate LV filling pressure. Unlike traditional LA measurements, LA strain offers detailed insights into LA function, conduit, and booster-pump phases, making it crucial for evaluating both structural and functional cardiac performance, especially in HFpEF. HFpEF diagnosis currently relies on a combination of echocardiographic parameters, clinical symptoms, and natriuretic peptide levels, encompassing various pathophysiological entities and complicating standardized management. Precise characterization of cardiac pathologies in HFpEF patients is essential. This review assesses global longitudinal strain (GLS) and left atrial strain (LAS) as echocardiographic biomarkers for diagnosing and characterizing HFpEF. Strain imaging, particularly speckle tracking echocardiography, offers a refined assessment of myocardial deformation, providing detailed insights into left heart function beyond traditional measures. Normal ranges for GLS and LAS are discussed, acknowledging demographic and technical influences. Clinical studies confirm the prognostic value of GLS and LAS in HFpEF, especially for predicting cardiovascular outcomes and distinguishing HFpEF from other dyspnea causes. However, variability in strain measurements and false-negative risks necessitate cautious clinical interpretation. The HFA-PEFF scoring system includes these biomarkers but does not fully cover the HFpEF pathology spectrum. Combining GLS and LAS shows promise in defining HFpEF phenogroups, potentially guiding individualized treatments. Global longitudinal strain (GLS) and left atrial strain (LAS) are central to non-invasive HFpEF diagnosis and stratification, with potential for more tailored therapies. Integration of these biomarkers into standard diagnostic practice requires an organized approach, and future guidelines should recommend their combined use for comprehensive HFpEF assessment. Full article
(This article belongs to the Special Issue Advancements in Heart Failure Research)
►▼ Show Figures

Figure 1

12 pages, 598 KiB  
Review
The Impact of Diet on Lipoprotein(a) Levels
by Michał Stojko, Aleksandra Spychał, Kamil Nikel, Rafał Kołodziej and Jolanta Zalejska-Fiolka
Life 2024, 14(11), 1403; https://doi.org/10.3390/life14111403 - 31 Oct 2024
Cited by 1 | Viewed by 2470
Abstract
Background: Lipoprotein(a) [Lp(a)] is recognized as an independent risk factor for cardiovascular diseases; however, the impact of fat-based diets on its levels remains unclear. Objective: This study aims to assess and analyze current evidence on the impact of various types of fat-based diets [...] Read more.
Background: Lipoprotein(a) [Lp(a)] is recognized as an independent risk factor for cardiovascular diseases; however, the impact of fat-based diets on its levels remains unclear. Objective: This study aims to assess and analyze current evidence on the impact of various types of fat-based diets on Lp(a) levels. Material and Methods: A comprehensive search of the PubMed database was conducted on 9 July 2024, focusing on clinical and randomized trials published since 2000. Out of 697 identified studies, 33 met the inclusion criteria and were selected for analysis. Results: The findings suggest that modifications in fat-based diets, particularly concerning the type and amount of consumed fats and fatty acids, can significantly influence plasma Lp(a) levels. Diets rich in unsaturated fats, including polyunsaturated and monounsaturated fatty acids, were associated with more favorable effects in lowering Lp(a) levels. In contrast, diets high in saturated fats were linked to elevated Lp(a) levels. However, these conclusions were not consistent across all studies considered. Conclusions: This work highlights the importance of a personalized dietary approach, considering both genetic predispositions and dietary habits. While diet alone may not drastically alter Lp(a) levels due to their strong genetic determination, a comprehensive strategy involving a healthy diet rich in unsaturated fats, regular physical activity, and effective weight management is recommended to reduce the risk of cardiovascular diseases. Further research is needed to clarify the mechanisms through which different fats affect Lp(a) and to develop targeted dietary recommendations. Full article
(This article belongs to the Special Issue Advancements in Heart Failure Research)
►▼ Show Figures

Figure 1

10 pages, 216 KiB  
Review
Unveiling the Potential: Remote Monitoring and Telemedicine in Shaping the Future of Heart Failure Management
by Ju-Chi Liu, Chun-Yao Cheng, Tzu-Hurng Cheng, Chen-Ning Liu, Jin-Jer Chen and Wen-Rui Hao
Life 2024, 14(8), 936; https://doi.org/10.3390/life14080936 - 25 Jul 2024
Cited by 7 | Viewed by 4244
Abstract
Heart failure (HF) remains a significant burden on global healthcare systems, necessitating innovative approaches for its management. This manuscript critically evaluates the role of remote monitoring and telemedicine in revolutionizing HF care delivery. Drawing upon a synthesis of current literature and clinical practices, [...] Read more.
Heart failure (HF) remains a significant burden on global healthcare systems, necessitating innovative approaches for its management. This manuscript critically evaluates the role of remote monitoring and telemedicine in revolutionizing HF care delivery. Drawing upon a synthesis of current literature and clinical practices, it delineates the pivotal benefits, challenges, and personalized strategies associated with these technologies in HF management. The analysis highlights the potential of remote monitoring and telemedicine in facilitating timely interventions, enhancing patient engagement, and optimizing treatment adherence, thereby ameliorating clinical outcomes. However, technical intricacies, regulatory frameworks, and socioeconomic factors pose formidable hurdles to widespread adoption. The manuscript emphasizes the imperative of tailored interventions, leveraging advancements in artificial intelligence and machine learning, to address individual patient needs effectively. Looking forward, sustained innovation, interdisciplinary collaboration, and strategic investment are advocated to realize the transformative potential of remote monitoring and telemedicine in HF management, thereby advancing patient-centric care paradigms and optimizing healthcare resource allocation. Full article
(This article belongs to the Special Issue Advancements in Heart Failure Research)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-11
Back to TopTop